BOULDER, Colo., Apr 26, 2012 (BUSINESS WIRE) --Array BioPharma Inc. (NASDAQ: ARRY) today announced that Ron Squarer has
been appointed Chief Executive Officer, effective immediately. Mr.
Squarer has also been named to the Array Board of Directors.
Mr. Squarer, 45, has extensive commercial, development and executive
leadership expertise from a 20-year career in the pharmaceutical
industry. Most recently he served as Chief Commercial Officer at Hospira
Inc., a global pharmaceutical and medical device company, where he was
responsible for delivering $4 billion in annual revenue and leading more
than 2,000 employees worldwide. Prior to this, Mr. Squarer was
responsible for strategy, new product development and commercialization,
acquisitions, partnerships and portfolio prioritization as Senior Vice
President, Global Marketing and Corporate Development. Mr. Squarer
joined Hospira from Mayne Pharma, an oncology-focused, global
pharmaceutical company, where he served as Senior Vice President, Global
Corporate and Business Development when Mayne was sold to Hospira for $2
billion in 2007. Earlier, Mr. Squarer held senior management roles at
both Pfizer, Inc., focused on global oncology commercial development,
and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the
U.S. and Europe. Mr. Squarer holds an MBA from the Kellogg School of
Management, Northwestern University and a bachelor's degree in
biochemistry from the University of California, Berkeley.
"We're delighted that Ron has accepted our offer to be Array's new CEO,"
said Kyle Lefkoff, Executive Chairman. "Ron's appointment is the
culmination of the Board's comprehensive selection process to identify
the best executive to lead Array to the registration and
commercialization of our oncology and inflammation portfolio. We
consider Ron an ideal fit for Array."
Mr. Squarer added, "I am delighted to join Array, a recognized leader in
small molecule drug development. Array is an exceptional company with 10
Array-invented drugs in Phase 2, as well as outstanding people, a strong
cash position and uniquely productive discovery and development
capabilities. I look forward to building on the company's many strengths
and working with the Board and employees to improve the lives of
patients and drive value for shareholders."
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Array has four core proprietary clinical programs: ARRY-614 for
myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for
pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded
clinical programs including two MEK inhibitors in Phase 2: selumetinib
with AstraZeneca and MEK162 with Novartis. For more formation on Array,
please go to www.arraybiopharma.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50255358&lang=en
SOURCE: Array BioPharma
Tricia Haugeto, 303-386-1193